Welch Capital Partners LLC NY reduced its holdings in shares of Celgene Co. (NASDAQ:CELG) by 4.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,030 shares of the biopharmaceutical company’s stock after selling 1,770 shares during the period. Celgene accounts for about 1.8% of Welch Capital Partners LLC NY’s investment portfolio, making the stock its 28th largest holding. Welch Capital Partners LLC NY’s holdings in Celgene were worth $5,400,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Thompson Davis & CO. Inc. lifted its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares during the period. Arcadia Investment Management Corp MI lifted its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares during the period. Guidant Wealth Advisors purchased a new position in Celgene during the 3rd quarter valued at about $119,000. Motco lifted its position in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 159 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in Celgene during the 2nd quarter valued at about $129,000. 79.85% of the stock is owned by institutional investors.
Celgene Co. (CELG) opened at $101.72 on Friday. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a twelve month low of $94.55 and a twelve month high of $147.17. The firm has a market cap of $80,090.00, a P/E ratio of 23.99, a PEG ratio of 0.65 and a beta of 1.77.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the previous year, the company earned $1.58 earnings per share. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. analysts anticipate that Celgene Co. will post 6.7 EPS for the current fiscal year.
CELG has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed a “buy” rating and issued a $173.00 target price on shares of Celgene in a report on Thursday, October 5th. Morgan Stanley cut shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a report on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and issued a $162.00 target price on shares of Celgene in a report on Thursday, September 21st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $162.00 target price on shares of Celgene in a report on Tuesday, September 26th. Finally, Vetr raised shares of Celgene from a “hold” rating to a “buy” rating and set a $146.58 target price for the company in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Celgene has an average rating of “Buy” and an average target price of $129.98.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/19/welch-capital-partners-llc-ny-sells-1770-shares-of-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.